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and Ayman O. Soubani, MD†
Introduction: The link between lung cancer and chronic obstructive
lung diseases (COPD) has not been well studied in women even
though lung cancer and COPD account for significant and growing
morbidity and mortality among women.
Methods: We evaluated the relationship between COPD and non-
small cell lung cancer in a population-based case-control study of
women and constructed a time course of chronic lung diseases in
relation to onset of lung cancer. Five hundred sixty-two women aged
18 to 74, diagnosed with non-small cell lung cancer and 564
population-based controls matched on race and age participated.
Multivariable unconditional logistic regression models were used to
estimate risk associated with a history of COPD, chronic bronchitis,
or emphysema.
Results: Lung cancer risk increased significantly for white women
with a history of COPD (odds ratios [OR]  1.85; 95% confidence
intervals [CI]: 1.21–2.81), but this was not seen in African American
women. Risk associated with a history of chronic bronchitis was
strongest when diagnosed at age 25 or earlier (OR  2.35, 95% CI:
1.17–4.72); emphysema diagnosed within 9 years of lung cancer
was also associated with substantial risk (OR  6.36, 95% CI:
2.36–17.13). Race, pack-years of smoking, exposure to environ-
mental tobacco smoke as an adult, childhood asthma, and exposure
to asbestos were associated with a history of COPD among lung
cancer cases.
Conclusions: In women, COPD is associated with risk of lung
cancer differentially by race. Untangling whether COPD is in the
causal pathway or simply shares risk factors will require future
studies to focus on specific COPD features, while exploring under-
lying genetic susceptibility to these diseases.
Key Words: Chronic obstructive lung diseases, Lung cancer, Epi-
demiology, Women, Tobacco smoke.
(J Thorac Oncol. 2009;4: 291–299)
Chronic obstructive lung diseases have been linked to lungcancer risk in multiple studies. These lung diseases share
multiple risk factors, most importantly cigarette smoking.
Approximately 15% of smokers will develop lung cancer
and/or chronic obstructive pulmonary disease (COPD) and 10
to 15% of individuals with either of these diseases are never
smokers.1,2 Once COPD is diagnosed, risk of developing lung
cancer increases about twofold,3–7 even among never smok-
ers.8 Similarly, risk of lung cancer increases with decreasing
forced expiratory volume in 1 second (FEV1); this was
reported even in smokers with only minimal decreases in
FEV1 of approximately 10%.9 A family history of COPD also
increases risk of lung cancer development10,11 suggesting a
common underlying genetic contribution to these diseases.
An area of current research focuses on whether COPD
pathogenesis directly affects the development of lung
cancer or is a variation in manifestation of disease from the
same exposures.
The definition of and diagnosis of COPD have evolved
over time and includes a combination of two diseases that are
frequently codiagnosed, chronic bronchitis and emphysema,
making COPD heterogeneous in observed clinical phenotype.
Emphysema is characterized by parenchymal destruction,
whereas chronic bronchitis is a small airways disease. Over-
all, COPD is characterized by airflow limitation that is usu-
ally progressive and associated with an abnormal inflamma-
tory response.
COPD is the fourth leading cause of mortality in the
United States. The death rates from COPD among women
have surpassed those among men, with mortality rates in
women increasing fivefold between 1971 and 2000.12 Studies
have shown that female smokers demonstrate a sharper de-
cline in FEV1 than their smoking male counterparts over
time13 and a recent meta-analysis found that at each quintile
of reduced FEV1, women were approximately twice as likely
as men to develop lung cancer.9 Lung cancer is the leading
cause of cancer death in women and mortality rates have only
recently begun to decline.14 The combination of increasing
incidence of COPD and the high mortality from lung cancer
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in women, make this a population of growing importance for
continued and renewed study.
In this case-control study, we evaluated the relationship
between chronic obstructive lung diseases collectively, and
emphysema and chronic bronchitis separately, and risk of
lung cancer in a large population-based group of women. We
also report on the time course of chronic lung diseases in
relation to onset of lung cancer.
PATIENTS AND METHODS
Study Subjects
Female residents of metropolitan Detroit, aged 18 to 74,
diagnosed with primary non-small cell lung cancer (NSCLC)
November 2001 to October 2005 were identified through the
population-based Metropolitan Detroit Cancer Surveillance
System, a participant in the National Cancer Institute’s Sur-
veillance, Epidemiology, and End Results program. In-person
interviews were completed with 577 women (54.5%); 129
women were too ill to participate, 89 women could not be
located, and 263 women refused. Women self-reporting race
other than African American or white (n  15) were ex-
cluded, leaving 562 cases included in the analysis.
Population-based controls were identified through ran-
dom digit dialing, frequency matched to cases on race and
five-year age group. Of the households willing to complete
the eligibility screening, 575 (69.7%) participated. Eleven
controls reporting a race other than African American or
white were excluded, leaving 564 controls included in the
analysis.
Data Collection
All local institutional and review boards approved this
study. Informed consent was obtained from each subject
before study participation. In-person interviews were con-
ducted to collect demographic information, smoking history,
health history, family history of cancer, and environmental
tobacco smoke (ETS) exposure.15 Medical history included
self-report of physician diagnoses of asthma, emphysema,
allergies, pneumonia, chronic bronchitis, COPD, tuberculo-
sis, and cancer. Reports of emphysema, COPD, and/or
chronic bronchitis were collapsed in the inclusive “chronic
obstructive lung disease” variable. Reference to COPD in the
Results section refers only to those subjects who reported a
diagnosis of COPD and not to the inclusive category. Only
individuals with lung diseases diagnosed more than 1 year
before lung cancer diagnosis (for cases) or interview (for the
controls) were considered affected to limit inclusion of
COPD diagnoses made in conjunction with the diagnosis of
lung cancer. COPD diagnoses made within 1 year of lung
cancer diagnosis are less likely to be associated with lung
cancer risk.
Follow-up for vital status and cause of death was
obtained from the Metropolitan Detroit Cancer Surveillance
System for case-only survival analysis. Yearly active fol-
low-up is conducted for all cases in the registry, with fol-
low-up rates exceeding 98%.
Statistical Analysis
Comparisons of dichotomous risk factors between
cases and controls were conducted using 2 tests; compari-
sons of means were conducted using Student t tests. Multi-
variable unconditional logistic regression models were used
to estimate odds ratios (OR) and 95% confidence intervals
(CI) associated with a history of any chronic obstructive lung
disease, chronic bronchitis, or emphysema. Models included
age, race, years of education, pack-years of smoking, current
body mass index (BMI), family history of lung cancer, and
regular use of adult strength aspirin (at least one pill three
times per week for at least 1 month). Analyses were stratified
on race, smoking status, smoking amount, age, and regular
aspirin use. Cox proportional hazards models were used to
evaluate the impact of chronic obstructive lung diseases on
survival of women with lung cancer, constructed in the same
manner as the logistic regression models. Survival analyses
were also stratified on race, smoking status, smoking amount,
and age at diagnosis of lung cancer/age at interview. Differ-
ences between the median times between lung diagnoses by
age at lung cancer diagnosis were evaluated using a median
two-sample test. All statistical analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Cases and controls did not differ significantly by age,
race, or history of pneumonia or asthma (Table 1). These
groups did differ significantly by history of chronic obstruc-
tive lung disease diagnoses, including the combined variable,
emphysema, COPD and chronic bronchitis, and childhood
diagnosis of bronchitis. As expected, cases started smoking at
an earlier age, had significantly higher levels of pack-years of
smoking and quit smoking at a significantly later age than
controls.
Table 2 presents stratified results for the risk of lung
cancer associated with the inclusive chronic obstructive lung
disease category and for individually reported diagnoses. For
the combined obstructive lung disease classification, a signif-
icantly increased risk was seen for the entire study population
(OR 1.67, 95% CI: 1.15–2.41) and in white women (OR
1.85; 95% CI: 1.21–2.81). No increase in risk was seen in
African American women. An increased risk was not identi-
fied in nonsmokers or light smokers; however, a significantly
increased risk was found among heavy smoking women
(OR  1.93; 95% CI: 1.18–3.15). This risk was seen in both
former and current smokers. For this combined lung disease
category, lung cancer risk was highest in women diagnosed
before age 55.
Controls were significantly more likely than cases to
report only one chronic obstructive lung disease-related ill-
ness (p  0.01). In particular, controls were more likely to
report only a simple COPD or chronic bronchitis diagnosis. The
number of chronic lung conditions was significantly higher in
cases than controls (p  0.004); 10% of cases reported two or
more illnesses whereas only 2% of controls did.
A history of emphysema was associated with a three-
fold increased risk of lung cancer (OR  3.21; 95% CI:
1.60–6.45) after adjusting for age, race, pack years, family
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history of lung cancer, education, current BMI, and regular
strength aspirin use (Table 2). Risk was high in white women
but was not statistically significantly elevated in African
American women. Very high ORs were reported for light
smokers (OR  12.92, 95% CI: 1.30–129) and earlier onset
lung cancer (OR  13.59, 95% CI: 1.49–124) most likely
TABLE 1. Subject Characteristics
Category Cases (N  562) Controls (N  564) p
Race
White 427 (76.0) 432 (76.6) 0.81
African American 135 (24.0) 132 (23.4)
Age (mean, SD) 60.1 (9.2) 59.4 (9.4) 0.20
Smoking status
Never 49 (8.7) 275 (48.8) 0.0001
Exsmokera 183 (32.6) 180 (31.9)
Current smoker 330 (58.7) 105 (18.6)
Unknown/not answered 0 (0) 4 (0.7)
Smoking history
Pack years (mean, SD) 46.6 (29.4) 25.1 (22.4) 0.0001
Age began smoking 16.8 (4.3) 17.4 (4.4) 0.07
Age last smoked (exsmokers only,
mean, SD)
48.7 (12.1) 39.6 (12.8) 0.0001
Ever diagnosed with pneumonia?
No 356 (63.4) 378 (67.0) 0.19
Yes 202 (35.9) 182 (32.3)
Unknown/not answered 4 (0.7) 4 (0.7)
Ever diagnosed with childhood pneumonia?
No 510 (90.7) 505 (89.5) 0.48
Yes 48 (8.6) 55 (9.8)
Unknown/not answered 4 (0.7) 4 (0.7)
Ever diagnosed with asthma?
No 457 (81.3) 465 (82.4) 0.62
Yes 102 (18.2) 96 (17.0)
Unknown/not answered 3 (0.5) 3 (0.5)
Ever diagnosed with childhood asthma?
No 528 (94.0) 543 (96.3) 0.06
Yes 31 (5.5) 18 (3.2)
Unknown/not answered 3 (0.5) 3 (0.5)
Ever diagnosed with chronic obstructive
lung disease?b
No 387 (68.9) 483 (85.6) 0.0001
Yes 175 (31.1) 81 (14.4)
Ever diagnosed with COPD?
No 513 (91.3) 541 (95.9) 0.0005
Yes 46 (8.2) 19 (3.4)
Unknown/not answered 3 (0.5) 4 (0.7)
Ever diagnosed with emphysema?
No 476 (84.7) 549 (97.4) 0.0001
Yes 85 (15.1) 12 (2.1)
Unknown/not answered 1 (0.2) 3 (0.5)
Ever diagnosed with chronic bronchitis?
No 439 (78.1) 498 (88.3) 0.0001
Yes 120 (21.4) 63 (11.2)
Unknown/not answered 3 (0.5) 3 (0.5)
Ever diagnosed with bronchitis as a child?
No 537 (95.6) 550 (97.5) 0.05
Yes 22 (3.9) 11 (2.0)
Unknown/not answered 3 (0.5) 3 (0.5)
a Quit at least 2 yr before diagnosis (cases) or interview (controls).
b Includes chronic bronchitis, emphysema, or chronic obstructive pulmonary disease (COPD).
SD, standard deviation.
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because emphysema was very rare in the controls in these
categories. Significantly elevated lung cancer risk on the order
of five to sixfold was associated with a history of emphysema in
former smokers and women never using aspirin regularly. Over-
all, a history of chronic bronchitis was associated with a 1.7-fold
increased risk of lung cancer (95% CI: 1.13–2.59) and an
approximately 1.5 to 3.1-fold increased risk of lung cancer
across strata, with highest risk in heavier smokers.
Table 3 presents lung cancer risk by age at diagnosis
and time since diagnosis for selected lung diseases. Lung
cancer risk did not vary by age at diagnosis of asthma or time
since diagnosis of asthma. Similar findings were seen for
pneumonia. Cases were significantly more likely to report an
early diagnosis of chronic bronchitis (on or before age 25,
reported in 6.9% of cases; OR  2.35, 95% CI: 1.17–4.72)
and a longer time between chronic bronchitis and lung cancer
was associated with the greatest risk. For emphysema, a
recent diagnosis (within 9 years of lung cancer; OR  6.36,
95% CI: 2.36–17.13) and an older age of diagnosis were
associated with the greatest increase in risk of lung cancer.
To further characterize the occurrence of chronic ob-
structive lung diseases and lung cancer, cases with and
without a chronic obstructive lung disease diagnosis were
compared for a variety of risk factors (Table 4). In univari-
able analyses, cases with a chronic obstructive lung disease
diagnosis were significantly older at diagnosis of lung cancer
(p  0.01), were significantly more likely to be white
(0.0003), and had significantly higher levels of all smoking
and most ETS exposure measures than cases without such a
history. In addition, cases with a diagnosis of chronic ob-
structive lung disease were significantly more likely to have
been exposed to asbestos or report a childhood diagnosis of
pneumonia or asthma (p  0.04, 0.05, 0.03, respectively).
These two groups of cases were not significantly different in
their current BMI, years exposed to ETS as a child, family
history of lung cancer, or stage at diagnosis. Although cases
with a history of chronic obstructive lung disease (38.9%)
were somewhat more likely than cases without such a history
(31.5%) to be diagnosed at a localized stage, this difference
was not statistically significant. In a multivariable model
constructed using a stepwise approach, race, pack-years of
smoking, exposure to ETS as an adult, childhood asthma, and
exposure to asbestos were associated with history of a chronic
obstructive lung disease among lung cancer cases (Table 5).
Figure 1 represents time lines for chronic obstructive
lung diseases and lung cancer diagnoses in cases less than 55
TABLE 2. Risk of NSCLC in Women Associated with a History of Chronic Obstructive Lung Disease, Emphysema, and
Chronic Bronchitis
Chronic Obstructive Lung Diseasea Emphysema Chronic Bronchitis
Category
Percent of Cases
Affected/Percent
of Controls
Affected ORb (95% CI)
Percent of Cases
Affected/Percent
of Controls
Affected ORb (95% CI)
Percent of Cases
Affected/percent
of Controls
Affected ORb (95% CI)
All subjects 31.1/14.4 1.67 (1.15–2.41) 15.1/2.1 3.21 (1.60–6.45) 21.5/11.2 1.71 (1.13–2.59)
Race
White 35.1/14.6 1.85 (1.21–2.81) 17.4/2.1 3.75 (1.69–8.32) 23.4/11.4 1.82 (1.13–2.92)
African American 18.5/13.6 1.11 (0.49–2.49) 8.1/2.3 1.86 (0.42–8.23) 15.6/10.6 1.38 (0.56–3.37)
Smoking history
Never smokers 4.1/12.7 0.34 (0.08–1.51) 0.0/0.7 NA 4.2/11.8 0.37 (0.08–1.65)
Light smokers (18
pack years)
19.4/12.1 2.29 (0.91–5.75) 6.9/0.7 12.92 (1.30–128.8) 13.9/9.3 2.29 (0.79–6.64)
Heavy smokers (18
pack years)
34.0/20.4 1.93 (1.18–3.15) 15.9/6.3 2.65 (1.24–5.68) 23.4/12.7 2.13 (1.19–3.80)
Smoking status
Former smokersc 32.8/13.9 2.03 (1.11–3.71) 18.6/2.2 5.33 (1.65–17.20) 19.1/11.1 1.51 (0.76–3.02)
Current smokers 34.2/20.0 1.93 (1.06–3.49) 15.5/5.7 2.33 (0.91–5.97) 25.3/10.5 3.08 (1.47–6.43)
Age at lung cancer
diagnosis/interview
55 yr 26.3/11.5 2.05 (1.01–4.19) 10.0/0.6 13.59 (1.49–124.3) 20.8/9.9 1.96 (0.91–4.18)
55 yr 33.1/15.8 1.54 (1.00–2.40) 17.2/2.9 2.53 (1.20–5.33) 21.8/11.8 1.63 (0.96–2.69)
Adult strength aspirin use
Never took aspirin
regularly
27.8/12.1 1.64 (1.05–2.57) 13.0/1.0 6.34 (2.13–18.87) 19.5/9.9 1.63 (0.99–2.68)
Took aspirin regularly
for at least one
month
40.4/21.0 1.74 (0.89–3.41) 20.6/5.4 1.69 (0.62–4.62) 27.2/15.0 1.86 (0.86–3.99)
a Includes chronic bronchitis, emphysema, or chronic obstructive pulmonary disease (COPD) diagnosis.
b Adjusted for age at diagnosis/interview, race (white/African American), pack years, family history of lung cancer, education (less than high school, high school or equivalent,
more than high school), current BMI, and adult aspirin use (ever/never).
c Quit at least 2 yr before diagnosis.
NSCLC, non-small cell lung cancer; BMI, body mass index; CI, confidence interval; OR, odds ratio.
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(Figure 1A) and 55 years of age and older (Figure 1B). The
lung disease histories are fairly similar in these two age
groups, but the time line is accelerated for all lung diseases in
women diagnosed with lung cancer before age 55. A history
of emphysema was more commonly reported among cases
diagnosed at or after age 55 (17%) when compared with cases
diagnosed at younger ages (10%) (p  0.03). Median time
between emphysema diagnosis and lung cancer diagnosis was
8.5 and 5 years in the two lung cancer diagnosis age groups,
respectively (p  0.30). Median time between any chronic
obstructive lung disease diagnosis and lung cancer diagnosis
(13.5 and 13 years) was also similar by age (p  0.92), but
the initial age at onset of the chronic obstructive lung disease
differed significantly (35.5 and 51 years, respectively, p 
0.001) suggesting a group of women with early onset of lung
diseases who are more susceptible to early onset lung cancer.
African American women with NSCLC were less likely
to be diagnosed with a chronic obstructive lung disease (19%)
than white women (35%) (p  0.0003). When diagnosed,
both chronic bronchitis and emphysema were diagnosed at
ages approximately 8 years older than white women with
these conditions (data not shown). This suggests the potential
for delay in diagnosis, underreporting, and/or underdiagnosis
in African American women.
Also evaluated was whether a history of chronic ob-
structive lung disease, emphysema, or chronic bronchitis
impacted survival among cases. We found no significant
differences in survival overall or when our data were strati-
fied on race, smoking status, smoking amount, or age at
diagnosis (data not shown).
DISCUSSION
This study supports previous findings of an association
between a history of chronic obstructive lung disease and
NSCLC after adjustment for smoking history, extending
previous work by including a large number of women and
African Americans. We also present a time line for onset of
lung cancer after chronic obstructive lung disease diagnoses.
Overall, lung cancer risk was increased in women reporting a
diagnosis of any chronic obstructive lung disease, emphy-
sema, and/or chronic bronchitis. Two prospective studies
reported similar findings with risk of lung cancer increased
almost threefold with a history of COPD (HR: 2.8, 95% CI:
1.8–4.4),3 and with an emphysema diagnosis on radiography
TABLE 3. Risk of NSCLC in Women Associated with Age and Years Since Diagnosis of Lung Diseases
Age at First Diagnosis
of Lung Disease
Number of
Cases/Number
of Controls Adjusted ORa 95% CI
Years Since First
Diagnosed with
Lung Disease
Number of
Cases/Number
of Controls Adjusted ORa 95% CI
Asthma
No 457/465 1.00 (ref) No 457/465 1.00 (ref)
0–25 35/29 1.07 (0.56–2.07) 2–9b 34/32 0.97 (0.50–1.91)
26–49 32/37 0.93 (0.68–1.27) 10–19 18/23 0.77 (0.52–1.14)
50 34/30 0.91 (0.72–1.15) 20 49/41 1.01 (0.84–1.22)
Pneumonia
No 356/378 1.00 (ref) No 356/378 1.00 (ref)
0–25 74/72 0.90 (0.57–1.40) 2–9b 53/36 1.34 (0.76–2.35)
26–49 82/74 1.04 (0.84–1.30) 10–19 33/27 1.04 (0.75–1.45)
50 46/36 0.96 (0.79–1.18) 20 116/119 0.95 (0.84–1.07)
Chronic bronchitis
No 439/498 1.00 (ref) No 439/498 1.00 (ref)
0–25 39/19 2.35 (1.17–4.72) 2–9b 31/15 1.71 (0.78–3.71)
26–49 45/26 1.21 (0.89–1.66) 10–19 27/18 1.03 (0.71–1.50)
50 36/18 1.12 (0.88–1.43) 20 62/30 1.30 (1.07–1.57)
Emphysema
No 476/549 1.00 (ref) No 476/549 1.00 (ref)
0–25 1/1 0.20 (0.01–3.34) 2–9b 61/5 6.36 (2.36–17.13)
26–49 21/2 2.61 (1.14–5.95) 10–19 20/4 1.11 (0.60–2.02)
50 63/9 1.44 (1.10–1.87) 20 4/3 0.78 (0.40–1.51)
Chronic obstructive lung diseasec
No 387/483 1.00 (ref) No 387/483 1.00 (ref)
0–25 40/21 2.08 (1.06–4.08) 2–9b 67/27 1.75 (1.00–3.06)
26–49 58/30 1.25 (0.93–1.67) 10–19 41/20 1.07 (0.76–1.51)
50 77/30 1.15 (0.95–1.38) 20 67/34 1.26 (1.05–1.51)
a Adjusted for age at diagnosis/interview, race (white/African American), pack years, family history of lung cancer, education (less than high school, high school or equivalent,
more than high school), current BMI, and ever/never adult aspirin use.
b Only individuals with lung diseases diagnosed more than 1 yr before lung cancer diagnosis (for cases) or interview (for the controls) were considered affected.
c Includes chronic bronchitis, emphysema, or chronic obstructive pulmonary disease (COPD).
NSCLC, non-small cell lung cancer; BMI, body mass index; CI, confidence interval; OR, odds ratio.
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TABLE 4. Subject Characteristics of Women with NSCLC, with and without Chronic Obstructive Lung Disease
Category
Cases without a Chronic Obstructive
Lung Disease Diagnosis (N  387)
Cases with a Chronic Obstructive
Lung Disease Diagnosis (N 
175) p
Race
White 277 (71.6) 150 (85.7) 0.0003
African American 110 (28.4) 25 (14.3)
Age at lung cancer diagnosis (mean, SD) 59.4 (9.5) 61.4 (8.6) 0.01
Current BMI (mean, SD) 26.2 (5.8) 26.6 (6.3) 0.46
Smoking status
Never 47 (12.1) 2 (1.1) 0.0001
Exsmokera 123 (31.8) 60 (34.3)
Current smoker 217 (56.1) 113 (64.5)
Smoking history for smokers only
Age began smoking 17.1 (4.4) 16.3 (4.1) 0.05
Pack years (exsmokers) (mean, SD) 35.2 (24.7) 52.5 (34.8) 0.0009
Pack years (current smokers) (mean, SD) 46.6 (27.5) 56.0 (30.9) 0.005
Age last smoked (exsmokers) (mean, SD) 47.1 (12.5) 52.0 (10.6) 0.01
Education
Less than high school 68 (17.6) 36 (20.6) 0.02
High school graduate or equivalent 145 (37.4) 82 (46.9)
At least some college 173 (44.7) 57 (32.5)
Unknown/not answered 1 (0.3) 0 (0)
Exposure to ETS as a child
No 94 (24.3) 29 (16.6) 0.04
Yes 293 (75.7) 146 (83.4)
Years (mean, SD among exposed) 16.6 (3.7) 16.0 (4.3) 0.16
Household exposure to ETS as an adult
No 88 (22.7) 20 (11.4) 0.002
Yes 298 (77.0) 155 (88.6)
Unknown/not answered 1 (0.3) 0 (0)
Years (mean, SD among exposed) 25.7 (16.1) 28.9 (13.8) 0.03
Work exposure to ETS
No 93 (24.0) 28 (16.0) 0.03
Yes 293 (75.7) 147 (84.0)
Unknown/not answered 1 (0.3) 0 (0)
Years (mean, SD among exposed) 16.0 (10.4) 17.6 (11.1) 0.13
Took adult strength aspirin regularly
No 302 (78.0) 116 (66.3) 0.005
Yes 81 (21.0) 55 (31.4)
Unknown/not answered 4 (1.0) 4 (2.3)
Exposed to asbestos
No 317 (81.9) 133 (76.0) 0.04
Yes 63 (16.3) 42 (24.0)
Unknown/not answered 7 (1.8) 0 (0)
First-degree family history of lung cancer
No 297 (76.7) 127 (72.6) 0.29
Yes 90 (23.3) 48 (27.4)
Childhood pneumonia
No 357 (92.2) 153 (87.4) 0.05
Yes 27 (7.0) 21 (12.0)
Unknown/not answered 3 (0.8) 1 (0.6)
Childhood asthma
No 370 (95.6) 158 (90.4) 0.03
Yes 16 (4.1) 15 (9.5)
Unknown/not answered 1 (0.3) 2 (0.1)
Stage at diagnosis
Local 122 (31.5) 68 (38.9) 0.19
Regional 127 (32.8) 57 (32.6)
Distant 132 (34.1) 49 (28.0)
Unknown 6 (1.6) 1 (0.5)
a Quit at least 2 yr before diagnosis (cases) or interview (controls).
NSCLC, non-small cell lung cancer; SD, standard deviation; BMI, body mass index; ETS, environmental tobacco smoke.
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after adjustment for extent of airflow obstruction (OR: 3.1;
95% CI: 1.9–5.2).7 Numerous case-control studies are also in
agreement.5,16,17
Our cases were significantly more likely to report
multiple chronic obstructive lung diseases than controls and
the timing of these illnesses seems to be distinct. We report
that an early age of diagnosis of chronic bronchitis was
related to a higher risk of lung cancer. In a previous analysis,
Wu et al.18 also found chronic bronchitis was associated with
a significant increase in lung cancer risk overall. Among their
population of nonsmoking women, however, a later age of
chronic bronchitis seemed to be associated with the most
significant risk. Schabath et al.5 also did a similar analysis and
found a borderline protective effect of chronic bronchitis
diagnosed 10 years before lung cancer diagnosis/interview.
Although we did not find a protective effect associated with
a 10 year lag time, we report null results for a 10 to 19 year
lag time. It was only with lag times of over 20 years that we
see increased lung cancer risk. These findings are not unex-
pected given that chronic bronchitis tends to be diagnosed
earlier than emphysema. Individuals with emphysema tend to
present later; however, once diagnosed they have a more
rapid deterioration of lung function.
We report that lung cancer is typically diagnosed closer
to an emphysema diagnosis than to a chronic bronchitis
diagnosis. Schabath et al.5 found emphysema to be signifi-
cantly related to an increased risk at all time periods before a
lung cancer diagnosis. Both men and women were included
in that study making it likely that smoking exposures were
higher overall than seen in our study of women only. Two
prospective studies show that smokers with an emphysema
diagnosis based on low-dose computed tomography of the
chest were at a threefold increased risk of developing lung
cancer than smokers without emphysema,7,19 at a rate of 25
lung cancers per 1000 person-years.19 This relationship held
even in individuals without airway obstruction based on
spirometry readings. Smokers with both emphysema and
airway obstruction were at even greater risk. These findings
suggest that lung cancer occurrence is linked differentially to
specific features of COPD.
African American women in our study were less likely
than white women to report a physician diagnosis of COPD.
This racial difference in prevalence has been reported previ-
ously.20 In addition, although lung cancer risk associated with
a previous chronic obstructive lung disease was elevated in
African American women, these findings were not statisti-
cally significant. Racial differences reported may be due to
FIGURE 1. Time lines of lung dis-
ease history in women with non-
small cell lung cancer. A, Women
diagnosed before age 55. B, Women
diagnosed on or after age 55.
TABLE 5. Risk Factors Associated with a History of Any
Chronic Obstructive Lung Disease in Women with NSCLC
Category
Univariable
OR (95% CI)
Multivariable
OR (95% CI)
Race (African American/white) 0.42 (0.26–0.68) 0.56 (0.34–0.93)
Age 1.02 (1.00–1.04) 1.02 (0.99–1.04)
Current BMI 1.01 (0.98–1.04)
Pack years 1.02 (1.01–1.02) 1.01 (1.01–1.02)
Age began smoking 0.95 (0.91–1.00)
Education (less than high school,
high school or equivalent, more
than high school)
0.76 (0.60–0.97)
Exposure to childhood ETS 1.62 (1.02–2.56)
Years of childhood ETS exposure 1.01 (0.99–1.04)
Exposure to adulthood ETS 2.29 (1.36–3.86) 2.02 (1.17–3.49)
Years of adulthood ETS exposure 1.02 (1.01–1.03)
Exposure to ETS at work 1.67 (1.05–2.66)
Years of work ETS exposure 1.02 (1.00–1.04)
Family history of lung cancer 1.25 (0.83–1.87)
Childhood pneumonia 1.82 (1.00–3.31)
Childhood asthma 2.20 (1.06–4.55) 2.42 (1.11–5.24)
Ever took aspirin regularly 1.77 (1.18–2.65)
Ever exposed to asbestos 1.59 (1.02–2.47) 1.69 (1.05–2.72)
NSCLC, non-small cell lung cancer; BMI, body mass index; ETS, environmental
tobacco smoke; CI, confidence interval; OR, odds ratio.
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underreporting, underdiagnosis, or lower risk of COPD
among African American women associated with lower
smoking exposures or genetic variations in susceptibility.
In previous published work based on this case-control
study, we reported that lung cancer risk was inversely asso-
ciated with use of adult strength aspirin.15 The association
between COPD or emphysema and lung cancer risk was
strongest in women reporting no regular aspirin use. The
association between COPD and lung cancer risk was still
elevated in women who did take aspirin regularly, although
these findings were not statistically significant. It has been
reported that use of inhaled corticosteroids among patients
with COPD might reduce risk of subsequent lung cancer.21
We did not collect information about inhaled corticosteroids.
The contribution of antiinflammatory drug use among women
with COPD to lung cancer risk should be further explored.
In characterizing the lung disease histories of women
with lung cancer, we report that lung cancer cases with a
chronic obstructive lung disease diagnosis were more likely
to be white, be heavy smokers, be exposed to ETS as an adult,
have childhood asthma, and have a history of asbestos expo-
sure. Each of these exposures are risk factors for both COPD
and lung cancer. Therefore, the unanswered question is
whether COPD is in the causal pathway in the development
of lung cancer or a variation in manifestation from the same
exposures. Shared risk factors include not only cigarette
smoking but also occupational exposures and asbestos expo-
sure.22 These exposures are associated with airway inflam-
mation.23 Brody and Spira24 review the pathways leading
from inflammation to COPD and lung cancer and suggest that
early on in the pathogenesis of these diseases divergent
pathways emerge.
In addition to shared exposures, a number of candidate
single gene polymorphisms have been associated with sus-
ceptibility to lung cancer and COPD.25–28 Common polymor-
phisms associated with both COPD and lung cancer are found
in genes coding for epoxide hydrolase 1, the matrix metallo-
protienases, and interleukin 1. Gene expression studies in
COPD and lung cancer also point to up- and down-regulation
of genes functioning in inflammation and oxidative stress in
both these diseases.29–31 Uncoupling shared risk factors from
causal pathways will be difficult.
This study has a number of strengths including its large
size, use of population-based cases and controls and a focus
on women, including a large minority population. However,
there are some limitations. The biggest limitation to this
study, and all studies that rely on self-report, is the possibility
of misclassification of history of lung disease. Given the
clinical complexities and changes in diagnostic classifications
over the years, it is probably most reasonable to use the
classification of any chronic obstructive lung disease that
combines women who report a history of COPD, chronic
bronchitis, and/or emphysema to limit potential misclassifi-
cation. Future studies need to include better defined COPD
phenotypes that include measures of severity.
This study adds to the substantial literature on COPD
and lung cancer by demonstrating an association between a
history of chronic obstructive lung diseases and the develop-
ment of NSCLC in women, a less frequently studied group. It
further shows that African American women with lung cancer
are less likely than white women with lung cancer to report a
previous lung disease suggesting that they are either under-
diagnosed or at lower risk of having such a diagnosis even
with similar smoking histories. Women diagnosed with lung
cancer before age 55 report a previous lung disease beginning
at an earlier age than women with later onset lung cancer.
These women represent a group of susceptible women who
might benefit from more intensive follow-up. Future studies
should focus on better defining chronic obstructive lung
diseases using spirometry and computed tomography, while
exploring underlying genetic susceptibility to these diseases.
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